NCM·Healthcare·$338M·#339 / 520 in Healthcare

ABEO Abeona Therapeutics Inc.

34HIGH RISK

CATEGORY BREAKDOWN

GROWTH0
QUALITY34
STABILITY57
VALUATION0
GOVERNANCE60

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

N/A
0

> 50% strong

Gross Margin

Revenue retained after direct costs

41.2%
57

> 50% strong

Cash Runway

Months of cash at current burn rate

12 months
41

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

15.7%
87

< 25% strong

Price / Sales

Market cap relative to trailing revenue

58.1x
0

< 3x strong

Rule of 40

Growth rate plus operating margin

N/A
0

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

16.8%
79

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+16.2%
21

< 5% ideal

SCORE HISTORY

COMPARE ABEO WITH…

ABEOvs

OR QUICK-COMPARE SECTOR PEERS

SCORE ALERT

Get notified when ABEO's score changes by 5+ points.

DATA INFO

Last updated: May 4, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.